Across TCGA pan-cancer cohorts, RALYL mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RALYL data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RALYL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RALYL expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where RALYL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.460	0.887	.024	6	view →
GBM	DFS	Quartile	All	0.425	0.206	.007	6	view →
PDAC	DFS	Quartile	II,III,IV	0.528	0.725	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RALYL tumor-vs-normal RNA expression · all RALYL data types